10/082,925 PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

John E. More et al.

February 26, 2002

Examiner:

Abdel Mohamed

Serial No.:

10/082,925

Group Art Unit: Docket:

1653 697.004US2

Filed: Title:

**PURIFICATION METHOD** 

## INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, JOHN E. MORE ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 371-2106

Katharine A Jackson Huebsch

Reg. No. 47,670

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Argendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this Level day of January, 2005

PTO/SB/084(10-01)
Approved for use through 10/31/2022. OMB 851-0031
US Parent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
work, Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. form 1449A/PTO MATION DISCLOSURE 10/082,925 **Application Number** TENT STEMENT BY APPLICANT February 26, 2002 **Filing Date** Use as many sheets as necessary) More, John **First Named Inventor** 1653 **Group Art Unit** Mohamed, Abdel **Examiner Name** Attorney Docket No: 697.004US2 Sheet 1 of 1

US PATENT DOCUMENTS								
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>			

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No <sup>1</sup>		
		KEYLER, DANIEL E., "Effects of Alpha-1-Acid Glycoprotein Administration on Propranolol Binding and Beta Blockade in Rats", <u>Biochemical Pharmacology</u> , Vol. 38, No. 7, (1989),1163-1168	
		KREMER, JOSEPHINA M., "Drug Binding to Human Alpha-1-acid Glycoprotein in Health and Disease", Pharmacological Reviews, Vol. 40, No. 1, (1988),1-47	
		SEABERG, DAVID C., "Effects of Alpha-1-acid Glycoprotein on the Cardiovascular Toxicity of Nortriptyline in a Swine Model", Vet Hum Toxicol, Vol. 33, No. 3, (June 1991),226-231	